VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma

Overview of attention for article published in OncoTargets and therapy, January 2017

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 16,057 followers.

RT @Myeloma_Doc: Iowa study shows VTD + ASCT provides very high rates of sCR and MRD-negativity in #myeloma (but TRM was 2.6%): https://t.c…

Iowa study shows VTD + ASCT provides very high rates of sCR and MRD-negativity in #myeloma (but TRM was 2.6%): https://t.co/0zruDyOtV6.